Cargando…

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors

Detalles Bibliográficos
Autores principales:	Cucchi, David G. J., Van Alphen, Carolien, Zweegman, Sonja, Van Kuijk, Bo, Kwidama, Zinia J., al Hinai, Adil, Henneman, Alexander A., Knol, Jaco C., Piersma, Sander R., Pham, Thang V., Jimenez, Connie R., Cloos, Jacqueline, Janssen, Jeroen J. W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202661/ https://www.ncbi.nlm.nih.gov/pubmed/34136754 http://dx.doi.org/10.1097/HS9.0000000000000606

Ejemplares similares

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
por: Beekhof, Robin, et al.
Publicado: (2019)

DNA vs cDNA FLT3-ITD allelic ratio and length measurements in adult acute myeloid leukemia
por: Cucchi, David G. J., et al.
Publicado: (2021)

Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines
por: Glykofridis, Iris E., et al.
Publicado: (2022)

Gene Expression Profiles Associated with Pediatric Relapsed AML
por: Bachas, Costa, et al.
Publicado: (2015)

Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML
por: Wojtuszkiewicz, Anna, et al.
Publicado: (2021)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
por: Roeten, Margot S.F., et al.
Publicado: (2021)

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2022)

P329: HIGH IMMUNOPROTEASOME ACTIVITY AS NOVEL INDICATOR FOR SENSITIVITY TO BORTEZOMIB-CONTAINING CHEMOTHERAPY IN ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS FROM CHILDREN’S ONCOLOGY GROUP TRIAL AALL1231
por: Roeten, Margot, et al.
Publicado: (2023)

UCB HCT in FLT3+ AML
por: Ustun, Celalettin, et al.
Publicado: (2017)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
por: Labots, Mariette, et al.
Publicado: (2020)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After α2-3–Linked Sialic Acid Ligand Binding
por: Li, Rui-Jún Eveline, et al.
Publicado: (2021)

Role of Biomarkers in FLT3 AML
por: Nitika,, et al.
Publicado: (2022)

Association of FLT3-internal tandem duplication length with overall survival in acute myeloid leukemia: a systematic review and meta-analysis
por: Polak, Tobias B., et al.
Publicado: (2022)

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies
por: Cordo’, Valentina, et al.
Publicado: (2022)

Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia
por: Cucchi, David G.J., et al.
Publicado: (2020)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML
por: Lam, Stephen S.Y., et al.
Publicado: (2020)

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment
por: van Beijnum, Judy R., et al.
Publicado: (2020)

Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors
por: Short, Nicholas J., et al.
Publicado: (2023)

A Review of FLT3 Kinase Inhibitors in AML
por: Negotei, Cristina, et al.
Publicado: (2023)

Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate
por: Rolfs, Frank, et al.
Publicado: (2021)

Inhibition of FLT3 Expression by Green Tea Catechins in FLT3 Mutated-AML Cells
por: Ly, Bui Thi Kim, et al.
Publicado: (2013)

Combination Therapies Targeting Apoptosis in Paediatric AML: Understanding the Molecular Mechanisms of AML Treatments Using Phosphoproteomics
por: Ali, Ahlam A., et al.
Publicado: (2023)

Targeting FLT3 mutations in AML: review of current knowledge and evidence
por: Daver, Naval, et al.
Publicado: (2019)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
por: Othman, Jad, et al.
Publicado: (2023)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2020)

Microenvironmental Hypoxia regulates FLT3 expression and biology in AML
por: Sironi, Silvia, et al.
Publicado: (2015)

Therapeutic Vulnerabilities in FLT3-Mutant AML Unmasked by Palbociclib
por: Uras, Iris Z., et al.
Publicado: (2018)

Re-assessment of the high-grade serous ovarian cancer phosphoproteome – Identification of kinase candidates in TCGA tumors for future clinical intervention
por: Rolfs, Frank, et al.
Publicado: (2019)

MRD Tailored Therapy in AML: What We Have Learned So Far
por: Ngai, Lok Lam, et al.
Publicado: (2021)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML
por: Kivioja, Jarno, et al.
Publicado: (2021)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
por: Yilmaz, Musa, et al.
Publicado: (2021)

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
por: Gosline, Sara J. C., et al.
Publicado: (2022)

Momelotinib is a highly potent inhibitor of FLT3-mutant AML
por: Azhar, Mohammad, et al.
Publicado: (2022)

Natural Flt3Lg-Based Chimeric Antigen Receptor (Flt3-CAR) T Cells Successfully Target Flt3 on AML Cell Lines
por: Maiorova, Varvara, et al.
Publicado: (2021)

Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3‐internal tandem duplication AML: The JALSG AML209‐FLT3‐SCT study
por: Kawashima, Naomi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_raht88gdi8mevhh4p3sejnmdns